Integra LifeSciences Holdings Corp (IART) stock
IARTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 23, 2026Score 9/308% below fair value
$13.55−0.43 (-3.08%)
Close on Nov 17, 2026Market cap $1.05BP/E 79.7Yield –
Integra LifeSciences r&d expenses
Research and development expenses are spending on new products and technology.
Integra LifeSciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $94.44M, down 10.4% year over year. For fiscal 2025 it was $98.97M, down 14.2% from the year before. Over ten years it grew 6.9% a year on average. The highest annual figure on record is $115.38M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $98.97M | -14.2% |
| FY2024 | Dec 31, 2024 | $115.38M | +10.7% |
| FY2023 | Dec 31, 2023 | $104.19M | +3.0% |
| FY2022 | Dec 31, 2022 | $101.19M | +8.8% |
| FY2021 | Dec 31, 2021 | $93.05M | +20.3% |
| FY2020 | Dec 31, 2020 | $77.38M | -2.8% |
| FY2019 | Dec 31, 2019 | $79.57M | +2.0% |
| FY2018 | Dec 31, 2018 | $78.04M | +23.0% |
| FY2017 | Dec 31, 2017 | $63.46M | +9.1% |
| FY2016 | Dec 31, 2016 | $58.16M | +14.3% |
| FY2015 | Dec 31, 2015 | $50.90M | +16.8% |
| FY2014 | Dec 31, 2014 | $43.56M | +2.2% |
| FY2013 | Dec 31, 2013 | $42.62M | -16.4% |
| FY2012 | Dec 31, 2012 | $51.01M | -0.9% |
| FY2011 | Dec 31, 2011 | $51.45M | +6.9% |
| FY2010 | Dec 31, 2010 | $48.11M | +8.7% |
| FY2009 | Dec 31, 2009 | $44.28M | -26.8% |
| FY2008 | Dec 31, 2008 | $60.50M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $21.90M | -2.5% |
| Q2 FY2026 | Jun 30, 2026 | $24.25M | -10.2% |
| Q1 FY2026 | Mar 31, 2026 | $23.50M | -5.0% |
| Q4 FY2025 | Dec 31, 2025 | $24.79M | -20.6% |
| Q3 FY2025 | Sep 30, 2025 | $22.46M | -18.1% |
| Q2 FY2025 | Jun 30, 2025 | $27.00M | -9.3% |
| Q1 FY2025 | Mar 31, 2025 | $24.73M | -8.3% |
| Q4 FY2024 | Dec 31, 2024 | $31.21M | +28.5% |
| Q3 FY2024 | Sep 30, 2024 | $27.44M | +3.2% |
| Q2 FY2024 | Jun 30, 2024 | $29.77M | +12.0% |
| Q1 FY2024 | Mar 31, 2024 | $26.97M | +0.9% |
| Q4 FY2023 | Dec 31, 2023 | $24.28M | -9.3% |
| Q3 FY2023 | Sep 30, 2023 | $26.60M | +7.5% |
| Q2 FY2023 | Jun 30, 2023 | $26.59M | +3.9% |
| Q1 FY2023 | Mar 31, 2023 | $26.72M | +11.0% |
| Q4 FY2022 | Dec 31, 2022 | $26.78M | +8.3% |
| Q3 FY2022 | Sep 30, 2022 | $24.74M | -4.2% |
| Q2 FY2022 | Jun 30, 2022 | $25.59M | +27.2% |
| Q1 FY2022 | Mar 31, 2022 | $24.09M | +7.6% |
| Q4 FY2021 | Dec 31, 2021 | $24.73M | +11.5% |
| Q3 FY2021 | Sep 30, 2021 | $25.83M | +32.7% |
| Q2 FY2021 | Jun 30, 2021 | $20.12M | +34.8% |
| Q1 FY2021 | Mar 31, 2021 | $22.37M | +7.5% |
| Q4 FY2020 | Dec 31, 2020 | $22.18M | -9.9% |
| Q3 FY2020 | Sep 30, 2020 | $19.46M | +2.4% |
| Q2 FY2020 | Jun 30, 2020 | $14.93M | -15.4% |
| Q1 FY2020 | Mar 31, 2020 | $20.82M | +13.6% |
| Q4 FY2019 | Dec 31, 2019 | $24.62M | +21.3% |
| Q3 FY2019 | Sep 30, 2019 | $19.00M | -6.4% |
| Q2 FY2019 | Jun 30, 2019 | $17.63M | -7.7% |
| Q1 FY2019 | Mar 31, 2019 | $18.32M | -0.0% |
| Q4 FY2018 | Dec 31, 2018 | $20.30M | +18.2% |
| Q3 FY2018 | Sep 30, 2018 | $20.31M | +35.1% |
| Q2 FY2018 | Jun 30, 2018 | $19.11M | +21.3% |
| Q1 FY2018 | Mar 31, 2018 | $18.33M | +18.3% |
| Q4 FY2017 | Dec 31, 2017 | $17.18M | +23.6% |
| Q3 FY2017 | Sep 30, 2017 | $15.03M | – |
| Q2 FY2017 | Jun 30, 2017 | $15.75M | – |
| Q1 FY2017 | Mar 31, 2017 | $15.49M | – |
| Q4 FY2016 | Dec 31, 2016 | $13.90M | – |
See a number that looks wrong?